About the Company

Grail, Inc. is a biotechnology company headquartered in Menlo Park, California, founded in 2015. The company focuses on alleviating the global burden of cancer through innovative multi-cancer early detection technologies. Its flagship product, the Galleri test, is a blood-based liquid biopsy that screens for multiple deadly cancer types at earlier, potentially more treatable stages, including those without existing recommended screening methods. Grail leverages next-generation sequencing, population-scale clinical studies, state-of-the-art machine learning, software, and automation to detect cancer signals from circulating cell-free DNA in the blood. The company conducts large-scale trials, such as the NHS-Galleri trial and PATHFINDER 2 study, to validate and refine its offerings. Grail also explores diagnostic aids for cancer suspicion and minimal residual disease monitoring. Operating in the healthcare and life sciences sectors, it partners with academic institutions, healthcare providers, and organizations to advance early cancer detection and improve patient outcomes worldwide.